F
43
3
SPG
53
2
SWKS
51
3
VIX
41
-2
C
50
2
CPB
55
8
BF.B
59
2
TGT
48
4
AIV
65
-2
CMI
55
4
ADI
61
4
WHR
50
7
GD
62
2
MCK
52
6
DHI
68
12
KEY
55
8
MCO
71
-3
DTE
63
4
ED
58
2
EMN
66
3
F
43
3
SPG
53
2
SWKS
51
3
VIX
41
-2
C
50
2
CPB
55
8
BF.B
59
2
TGT
48
4
AIV
65
-2
CMI
55
4
ADI
61
4
WHR
50
7
GD
62
2
MCK
52
6
DHI
68
12
KEY
55
8
MCO
71
-3
DTE
63
4
ED
58
2
EMN
66
3
Financhill
Back

Protalix BioTherapeutics 10K Form

Buy
57

PLX
Protalix BioTherapeutics

Last Price:
1.08
Seasonality Move:
79.27%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLX News And Ratings

See the #1 stock for the next 7 days that we like better than PLX

PLX Financial Statistics

Sales & Book Value

Annual Sales: $65.49M
Cash Flow: $-3.78M
Price / Cash Flow: 0
Annual Sales: $0.39
Price / Book: 2.8

Profitability

EPS (TTM): -0.23000
Net Income (TTM): $-14.69M
Gross Margin: $42.51M
Return on Equity: -43.43%
Return on Assets: -16.63%

Protalix BioTherapeutics Earnings Forecast

Key Protalix BioTherapeutics Financial Ratios

  • The Gross Profit Margin over the past 26 years for PLX is 64.91%.
  • The Selling, General & Administrative Expenses for PLX have been equal to 22.84% of Gross Profit Margin.
  • The Research & Development expenses have been 26.10% of Revenue.
  • The Interest Expense is 38.26% of Operating Income.
  • The Net Earning history of PLX is 12.69% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Protalix BioTherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PLX
CUSIP: 74365A
Website: protalix.com

Debt

Debt-to-Equity Ratio: 0.71
Current Ratio: 1.33
Quick Ratio: 0.95

Price-to-Earnings

Trailing P/E Ratio: 12.11
Forward P/E Ratio: 0

PLX Technical Analysis vs Fundamental Analysis

Buy
57
Protalix BioTherapeutics (PLX) is a Buy

Is Protalix BioTherapeutics a Buy or a Sell?